Influenza Vaccine Enhancement with Immunomodulating Peptide Thymosin Alpha 1 - Clinical studies have shown that treatment with thymosin alpha 1 increases response to vaccination. - BioPharm


Influenza Vaccine Enhancement with Immunomodulating Peptide Thymosin Alpha 1
Clinical studies have shown that treatment with thymosin alpha 1 increases response to vaccination.

BioPharm International Supplements


Clinical studies have shown that treatment with thymosin alpha 1 increases response to vaccination, providing up to six times the typical response seen. In these studies, thymosin alpha 1 was provided as a dose of about 1.6 mg/kg (0.9 mg/m2), injected twice-weekly after vaccination. Future studies will evaluate higher doses, which could allow for a shorter course of administration.

Thymosin alpha 1 is one of only a few immunomodulating compounds that have been approved for human use and does not appear to induce any of the side effects and toxicities commonly associated with agents in this class, such as interferon and interleukin-2. Thymosin has shown great utility in subjects older than 80 years of age, and was even used safely in patients as old as 101 years. Taken together, these data support the use of treatment with thymosin alpha 1 to increase response to vaccination.

Cynthia W. Tuthill is senior vice president and chief scientific officer at SciClone Pharmaceuticals, Inc., Foster City, CA, 650.358.3450,
Stefan Gravenstein is professor of medicine, Brown University and clinical director, quality improvement, at Quality Partners, Providence, RI, and William B. Ershler is deputy clinical director, clinical research branch, intramural research program, National Institute of Aging, National Institutes of Health, Baltimore, MD, and director at the Institute for Advanced Studies in Geriatric Medicine, Gaithersburg, MD.


1. Goldstein AL, Low TL, McAdoo M, McClure J, Thurman GB, Rossio J, et al. Thymosin alpha1: isolation and sequence analysis of an immunologically active thymic polypeptide. Proc Natl Acad Sci USA. 1977;74(2):725–9.

2. Ho AD, Ma DD, Price G, Hunstein W, Hoffbrand AV. Biochemical and immunological differentiation of human thymocytes induced by thymic hormones. Immunol. 1983;50(3):471–6.

3. Ho AD, Stehle B, Dietz G, Hunstein W, Hoffbrand AV. Terminal differentiation of cord blood lymphocytes induced by thymosin fraction 5 and thymosin alpha 1. Scand J Immunol. 1985;21(3):221–5.

4. Knutsen AP, Freeman JJ, Mueller KR, Roodman ST, Bouhasin JD. Thymosin-alpha1 stimulates maturation of CD34+ stem cells into CD3+4+ cells in an in vitro thymic epithelia organ coculture model. Int J Immunopharmacol. 1999;21(1):15–26.

5. Ohta Y, Sueki K, Yoneyama Y, Tezuka E, Yagi Y. Immunomodulating activity of thymosin fraction 5 and thymosin alpha 1 in immunosuppressed mice. Cancer Immunol Immunotherapy 1983;15:108–13.

6. Ohta Y, Tezuka E, Tamura S, Yagi Y. Thymosin alpha 1 exerts protective effect against the 5-FU induced bone marrow toxicity. Int J Immunopharmacol. 1985;7:761–68.

7. Ahmed A, Wong D. T-lymphocyte maturation: cell surface markers and immune functions induced by T-lymphocyte cell-free products and thymosin polypeptides. Annals New York Academy Sci. 1979;332:81–94.

8. Serrate S, Schulof R, Leondaridis L, Goldstein AL, Sztein MB. Modulation of human natural killer cell cytotoxic activity, lymphokine production, and interleukin 2 receptor expression by thymic hormones. J Immunol. 1987;139:2338–343.

9. Di Francesco P, Pica F, Gaziano R, Favalli C, Garaci E. In vivo recovery of natural killer cell activity by the association of thymosin a 1 and cytokines during cocaine administation. Med Sci Res. 1994;22:41-42.

10. Favalli C, Mastino A, Jezzi T, Grelli S, Goldstein AL, Garaci E. Synergistic effect of thymosin alpha 1 and alpha beta-interferon on NK activity in tumor-bearing mice. Int J Immunopharmacol. 1989;11(5):443–50.

11. Sztein M, Serrate S, Goldstein A. Modulation of interleukin-2 receptor expression on normal human lymphocytes by thymic hormones. Proc Natl Acad of Sci USA. 1986;83:6107–111.

12. Sztein M, Serrate S. Characterization of the immunoregulatory properties of thymosin alpha 1 on interleukin-2 production and interleukin-2 receptor expression in normal human lymphocytes. Int J Immunopharmacol. 1989;11:789–800.

13. Svedersky L, Hui A, May L, McKay P, Stebbing N. Induction and augmentation of mitogen-induced immune interferon production in human peripheral blood lymphocytes by Na-desacetylthymosin alpha 1. Eur J Immunol. 1982;12:244–47.

14. Hsia J, Sarin N, Oliver JH, Goldstein AL. Aspirin and thymosin increase interleukin-2 and interferon-gamma production by human peripheral blood lymphocytes. Immunopharmacol. 1989;17(3):167–173.

15. Leichtling KD, Serrate SA, Sztein MB. Thymosin alpha 1 modulates the expression of high affinity interleukin-2 receptors on normal human lymphocytes. Int J Immunopharmacol. 1990;12:19–29.

16. Mutchnick MG, Appelman HD, Chung HT, Aragona E, Gupta TP, Cummings GD, et al. Thymosin treatment of chronic hepatitis B: a placebo-controlled pilot trial. Hepatol. 1991;14:409–15.

17. Cursaro C, Margotti M, Favarelli L, Ferri E, Gramenzi A, Di Giammarino L, et al. Thymosin alpha 1 plus interferon alpha enhance the immune and antiviral response of patients with hepatitis C virus infection. Hepatol. 1998;28(4):361A.

blog comments powered by Disqus



FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Contract Research and Manufacturing Organization Paragon Bioservices Raises $13 Million
October 28, 2014
Yale and Gilead Extend Sequencing Initiative
October 28, 2014
Author Guidelines
Source: BioPharm International Supplements,
Click here